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C A N C E R
Unexpected contribution of lymphatic vessels to 
promotion of distant metastatic tumor spread
Qiaoli Ma1, Lothar C. Dieterich1, Kristian Ikenberg1,2, Samia B. Bachmann1, Johanna Mangana3, 
Steven T. Proulx1, Valerie C. Amann3, Mitchell P. Levesque3, Reinhard Dummer3, Peter Baluk4, 
Donald M. McDonald4, Michael Detmar1*
Tumor lymphangiogenesis is accompanied by a higher incidence of sentinel lymph node metastasis and shorter 
overall survival in several types of cancer. We asked whether tumor lymphangiogenesis might also occur in distant 
organs with established metastases and whether it might promote further metastatic spread of those metastases 
to other organs. Using mouse metastasis models, we found that lymphangiogenesis occurred in distant lung 
metastases and that some metastatic tumor cells were located in lymphatic vessels and draining lymph nodes. In 
metastasis-bearing lungs of melanoma patients, a higher lymphatic density within and around metastases and 
lymphatic invasion correlated with poor outcome. Using a transgenic mouse model with inducible expression of 
vascular endothelial growth factor C (VEGF-C) in the lung, we found greater growth of lung metastases, with more 
abundant dissemination to other organs. Our findings reveal unexpected contributions of lymphatics in distant 
organs to the promotion of growth of metastases and their further spread to other organs, with potential clinical 
implications for adjuvant therapies in patients with metastatic cancer.
INTRODUCTION
Tumor lymphangiogenesis plays an important role in cancer pro-
gression to sentinel lymph nodes (1, 2), and expression of the lymph-
angiogenic factor vascular endothelial growth factor C (VEGF-C), 
higher lymphatic vessel (LV) density, and the presence of tumor 
cells within LVs, termed lymphatic invasion, are associated with 
poor prognosis in many different types of cancer (1–3). Lymph-
angiogenesis also occurs in the sentinel lymph node, sometimes 
even before the arrival of metastatic tumor cells, stimulated by 
lymphangiogenic factors drained from the primary tumor (4–6). 
Besides providing a route for metastatic tumor cells, LVs might also 
contribute to tumor progression by providing a “niche” for cancer 
stem-like cells (7), which might facilitate the formation of “in-transit” 
melanoma metastases. Lymphatic endothelial cells (LECs) in primary 
tumors and tumor-draining lymph nodes might also present tumor 
antigens and suppress CD8+ T cell activation (8), thereby protecting 
metastatic cells from antitumor immune reactions.
Sentinel lymph node metastasis represents an important prog-
nostic indicator for systemic spread and for reduced survival in 
many cancer types, including melanoma and breast cancer. While 
recent studies indicated that cancer cells colonizing the sentinel 
lymph node might contribute to the seeding of visceral organ metas-
tasis (9–11), surgical resection of regional lymph nodes did not im-
prove the overall survival rate compared to radiation and systemic 
therapy without surgical resection of regional lymph nodes in breast 
cancer and melanoma patients (12–14). Thus, it currently remains a 
conundrum how tumor and lymph node lymphangiogenesis might 
contribute to reduced patient survival. Recently, genome sequencing 
studies of multiple organ and lymph node metastases of prostate 
cancer patients have provided evidence that organ-to-organ metas-
tasis might be commonly occurring in cancer (10, 11). This led us to 
hypothesize that lymphangiogenesis occurring within metastases 
might enable those metastases to seed additional metastases in other 
organs.
Here, we used two metastasis mouse models, a B16F10 melanoma 
model and an orthotopic 4T1 breast cancer model, to investigate 
whether lymphangiogenesis occurs at distant sites and might be 
correlated with further metastases. We also used a genetic mouse 
model to increase LV density in the lungs and investigated the 
growth of experimental melanoma- and breast cancer–derived lung 
metastases and spread from the lungs to other organs. Furthermore, 
we retrospectively analyzed 266 melanoma patients with lung me-
tastases and quantified LVs in resected lung tissue with metastases 
in a subgroup of 26 patients. Our findings reveal an unanticipated 
role of LVs in the promotion of the growth of metastases established 
in distant organs and their further metastatic spread to other organs, 
with potential clinical implications for adjuvant therapies in patients 
with metastatic cancer.
RESULTS
Lymphangiogenesis occurs in metastasis-bearing lungs
Tumor-associated lymphangiogenesis is commonly seen in primary 
tumors and sentinel lymph nodes and is associated with poor prog-
nosis (1, 2). We wondered whether lymphangiogenesis might also 
occur in distant organ metastases. Therefore, we orthotopically im-
planted spontaneously metastasizing 4T1 breast cancer cells into the 
fourth mammary fat pad and removed the primary tumors 21 days 
later. A further 21 days after primary tumor removal, when most 
mice had developed overt lung metastasis, we compared the lym-
phatic density in the control lungs and non-nodule covered area in 
the lungs of 4T1-injected mice. Thy1 (15–17) was used to identify 
pulmonary LVs, and cytokeratin was used to identify 4T1 cells 
(Fig. 1A and fig. S1). The lung area occupied by LVs was significantly 
larger in 4T1-injected mice compared with naïve lungs (4.86 ± 2.00% 
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Fig. 1. Lymphangiogenesis in metastasis-bearing lungs. 4T1-luc2 cells (1 × 105) were orthotopically inoculated, and after 21 days, the primary tumors were removed. 
Twenty-one days after the operation, mice were sacrificed for analysis. (A) Representative images of a naïve lung and a metastasis-bearing lung. White dashed line indi-
cates the edge of a metastatic nodule. Scale bars, 500 m. (B) Quantification of Thy1+ area in the lungs of control mice and non-nodule covered lung area of 4T1-injected 
mice (n = 12). (C) Quantification of the lung-draining (tracheobronchial) lymph node (LN) weight (n = 12). (D) Representative images of 4T1 cells metastasized to a tra-
cheobronchial lymph node. Scale bar, 50 m. (E and F) Prox1-GFP mice were inoculated with 5 × 105 B16F10-luc2-tdTomato cells intravenously and were sacrificed on 
days 7, 14, and 21 after injection. (E) Representative images of lungs and tracheobronchial lymph nodes. Lymph nodes were imaged in situ using a fluorescence stereo-
microscope. Scale bars, 500 m. (F) Correlation between lung metastasis (quantified by bioluminescence signal from B16F10-luc2-tdTomato cells) and lymph node weight 
(n = 11). Nonparametric correlation (Spearman) with nonlinear regression analysis was performed.
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versus 2.35 ± 0.73%, P < 0.01, Fig. 1B). We next investigated the 
tracheobronchial lymph nodes of 4T1-injected mice. The weight of 
lung-draining lymph nodes in these mice was significantly greater 
than in normal controls (2.29 ± 0.90 mg versus 0.86 ± 0.40 mg, P < 
0.001, Fig. 1C). Because a weight increase of tumor-draining lymph 
nodes is not an exact measure for metastatic colonization, we next 
performed immunofluorescence staining of the lymph nodes for cyto-
keratin. Tumor cells were detected in about 30% of the lung-draining 
lymph nodes (Fig. 1D). Comparable results were obtained in an experi-
mental melanoma metastasis model, in which B16F10 melanoma cells 
expressing luciferase (luc2) and the fluorescent reporter tdTomato 
were injected into the tail vein. The resulting metastases in the lungs 
were accompanied by an increased tdTomato fluorescence signal in 
the draining lymph nodes (Fig. 1E), and there was a significant cor-
relation between the extent of lung metastases (quantified by biolumi-
nescence) and the weight of the lung-draining lymph nodes (Spearman 
correlation, P = 0.018; nonlinear regression, r2 = 0.42; Fig. 1F). To-
gether, these data reveal that, as in the primary tumor, lymphangio-
genesis also occurred in metastases. Therefore, we next investigated 
whether lymphangiogenesis at sites of metastasis might contribute to 
further tumor spread to other organs and correlate with poor pa-
tient outcome.
High lymphatic density and lymphatic invasion  
in metastasis-bearing lungs correlate with poor prognosis  
in melanoma patients
To study the prognostic relevance of lymphangiogenesis at sites of 
metastasis, we conducted a retrospective study of 266 melanoma 
patients with lung metastasis (fig. S2A). Tumor cells in lung-draining 
lymph nodes (fig. S2B) were detected in 60.2% of the 266 patients. 
Surgically resected lung samples were available from 26 of these 
patients (fig. S2C). LVs stained for podoplanin with the D2-40 anti-
body were quantified around (Fig. 2A and fig. S3A) and within metas-
tases in the lungs (Fig. 2B and fig. S3, B and C). The area covered by 
lymphatics (Fig. 2C) and LV density (the number of LVs per square 
millimeter) (fig. S3D) were significantly greater around lung metas-
tases in patients who also had metastases in lung-draining lymph 
nodes (3.73 ± 2.09% versus 2.05 ± 1.50%, P < 0.05, Fig. 2C; 33.93 ± 
19.33 LV/mm2 versus 18.64 ± 12.49 LV/mm2, P < 0.05, fig. S3D). 
Similarly, the lymphatic area was greater within metastases in pa-
tients who also had metastases in lung-draining lymph nodes (2.09 ± 
1.70% versus 1.00 ± 0.47%, P < 0.05, Fig. 2D). The LV density showed 
the same trend without reaching significance (30.94 ± 25.45 LV/mm2 
versus 19.6 ± 14.97 LV/mm2, P = 0.22, fig. S3E). Patients with lym-
phatic area and lymphatic density values around metastases above 
the median had a significantly shorter survival time than those with 
values below the median (14.07 ± 2.16 months versus 38.69 ± 5.44 
months, P = 0.001, Fig. 2E; 17.02 ± 3.17 months versus 36.47 ± 6.08 
months, P = 0.019, fig. S3F). Similarly, high values for lymphatic 
area within metastases correlated with poor prognosis (16.87 ± 2.97 
months versus 35.87 ± 6.54 months, P = 0.045, Fig. 2F). The differ-
ence in LV density was not significant but followed the same trend 
(21.09 ± 5.62 months versus 33.45 ± 5.73 months, P = 0.16, fig. S3G).
In melanoma, lymphatic invasion in the primary tumor is fre-
quently related to sentinel lymph node metastasis and correlates with 
poor prognosis (18, 19). We next analyzed the incidence of lymphatic 
invasion (Fig. 2G) at the site of lung metastases. Lymphatic invasion, 
defined by the presence of tumor cells within D2-40– positive LVs, 
was seen more frequently in patients with metastases in lung-draining 
lymph nodes than in those without (12 of 15 versus 2 of 11, P = 
0.0043, Fig. 2H). Furthermore, patients with lymphatic invasion had 
a shorter survival time (19.56 ± 2.94 months versus 36.03 ± 7.21 months, 
P = 0.085, Fig. 2I). These data provide the first clinical evidence that 
lymphatic density within and around metastases and lymphatic in-
vasion correlate with poor prognosis. These findings also raise the 
possibility that LVs support the growth of metastases and/or facili-
tate further tumor spread to other organs.
Immune cell infiltration is commonly seen in many types of tu-
mors, and its prognostic value has been reported (20, 21). Immune 
cells are important players in the tumor microenvironment, actively 
interacting with other tumor-surrounding components, including 
tumor-associated LVs. To study the potential correlation between 
immune cell infiltration and lymphangiogenesis, the degree of im-
mune cell infiltration in the lung sections with melanoma metastases 
was scored semiquantitatively by a board-certified pathologist (fig. 
S4A), and the LV density (percentage of tissue area covered by LVs) 
was analyzed for each sample. There was a clear trend for an in-
creased LV density in the group of patients with a higher degree of 
immune cell infiltration; however, no statistical significance was 
reached [P = 0.052, one-way analysis of variance (ANOVA); fig. S4B]. 
We also compared the degree of immune cell infiltration between 
patients with and without lung-draining lymph node metastasis (fig. 
S4C). Statistical analysis (2 test) did not detect a significant difference 
(P = 0.18); however, the patients with the highest degree of immune 
cell infiltration all had metastases in the lung-draining lymph node.
Inducible transgenic overexpression of VEGF-C  
in the lungs of mice results in increased LV density
To study the function of LVs at sites of distant metastasis in more 
detail, we used an inducible, Clara cell promoter-driven transgenic 
mouse model to overexpress VEGF-C in the airway (CCSP-rtTA × 
tet-O–VEGF-C; CCSP × VEGFC) (22, 23).
In pilot studies, we induced VEGF-C overexpression in 8-week-
old mice by applying different concentrations of doxycycline for 
2 weeks to identify a dose that reliably induces LV growth without 
causing chylothorax. On the basis of these studies, a doxycycline 
concentration of 1 mg/ml was chosen for mice in the C57BL/6 
background and 2 mg/ml for mice in the BALB/c background. After 
2 weeks of doxycycline treatment of C57BL/6 mice, VEGF-C mRNA 
expression in the lung was increased more than 25-fold compared 
to control wild-type × tet-O–VEGF-C (WT × VEGFC) mice (P < 
0.001, Fig. 3A). The VEGF-C protein concentration in the lung in-
creased to 141.7 ± 22.24 pg/mg tissue compared to 80.67 ± 23.5 pg/mg 
tissue in control mice (P = 0.001, Fig. 3B). Accordingly, the area of 
VEGFR3+ (VEGF receptor 3–positive) lymphatics was almost three-
fold greater than in controls (8.66 ± 1.95% versus 2.98 ± 0.25%, P < 
0.01; Fig. 3, C and D). Lung lymphatics around bronchi and pulmonary 
veins were more abundant but otherwise appeared normal. Lym-
phatics were also more abundant beneath the visceral pleura of 
CCSP × VEGFC mice but were sparse or absent in controls (Fig. 3E). 
The morphology (Fig. 3F) and density (Fig. 3G) of blood vessels were 
not affected by VEGF-C overexpression.
Metastasis in lungs and other organs is greater in mice with 
VEGF-C overexpression in the lungs
To determine whether lymphatic growth induced by VEGF-C overex-
pression in the lung increased metastases, 5 × 105 B16F10-luc2- tdTomato 
tumor cells were injected via the tail vein of doxycycline-treated 
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CCSP × VEGFC mice, and 14 days later, the metastatic load in the 
lungs was evaluated by measuring the tdTomato [red fluorescent 
protein (RFP)]–positive area (Fig. 4A). WT × VEGFC mice were used 
as controls. This analysis revealed greater metastatic growth (20.69 ± 
8.54% versus 14.42 ± 3.82%, P < 0.05; Fig. 4, B and C) in the lungs of 
CCSP × VEGFC mice. Measurements of tdTomato-positive cells at 
24 hours after intravenous injection indicated that the difference did 
not reflect greater initial tumor cell homing to the lungs of CCSP × 
VEGFC mice (Fig. 4D). Fourteen days after tumor cell injection, the 
number of metastatic nodules in the lung was also comparable (fig. 
S5A). In VEGF-C–overexpressing mice, there were slightly, but not 
significantly, more large- and medium-sized nodules compared with 
control mice (fig. S5B). Most metastatic nodules were near bronchi, 
whereas in control mice, metastatic nodules were scattered through-
out the lungs, including near the pleural surface. The incidence of 
lymphatic invasion was greater in VEGF-C–overexpressing lungs 
(6 of 10 versus 0 of 10, P = 0.0034, Fig. 4E), as was the weight of the 
lung-draining lymph nodes (3.59 ± 1.34 mg versus 2.45 ± 0.67 mg, 
P < 0.05, Fig. 4F). Metastases were also more numerous in other 
organs of mice with VEGF-C overexpression in the lungs. In the 
CCSP × VEGFC group, 10 of 15 mice had metastases in other organs 
beside the lungs, while in the control group, only 3 of 15 mice also 
had metastases in other organs, indicating that CCSP × VEGFC mice 
are 7.4 times more likely to have metastasis in other organs compared 
to the control group (odds ratio, 7.4; P = 0.025, Fisher’s exact test). 
Furthermore, we quantified the number of organs with metastasis 
including the liver, intestine, brain, and kidney in each mouse (Fig. 4G) 
and performed a quasi-Poisson regression analysis to estimate 
Fig. 2. High lymphatic density and lymphatic invasion in metastasis-bearing lungs correlate with poor prognosis of melanoma patients. (A and B) Representative 
images of lymphatic hotspots (stained for podoplanin) around (A) and within (B) metastases in the lung. The metastasis area is labeled with “M.” Scale bars, 200 m. (C and 
D) Quantification of the percentage of lymphatic area around (C) and within (D) metastases in the lungs of patients without (white bars; n = 11) and with (black bars; n = 15) 
lung-draining lymph node metastasis. (E and F) Kaplan-Meier survival analysis of patients with low lymphatic area (below median; n = 13) and high lymphatic area (above 
median; n = 13) around (E) and within (F) metastases in the lungs. (G) Representative image of lymphatic invasion in a melanoma lung metastasis. Scale bar, 200 m. Tissues 
shown in (B) and (G) were located within a larger metastatic region containing cancer cells (see fig. S3C). (H) Quantification of incidence of lymphatic invasion in patients 
without (n = 11) and with (n = 15) lung-draining lymph node metastasis. Fisher’s exact test was performed. (I) Kaplan-Meier survival analysis of patients with (+; n = 14) 
and without (−; n = 12) lymphatic invasion. The time axes indicate the time from detection of lung metastases until death. Log-rank (Mantel-Cox) test was performed.
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the expected number of affected organs per animal. CCSP × 
VEGFC mice had 3.6 times more organs affected than control mice 
(1.2 organs per mouse in CCSP × VEGFC mice versus 0.33 in 
control mice; P = 0.025), suggesting a greater spread of melanoma 
cells through lung lymphatics.
VEGF-C expressed in the lung could reach the circulation and 
promote lymphatic growth and metastasis in other organs. We 
addressed this issue by measuring VEGF-C mRNA expression, 
protein levels, and LV density and morphology in the liver and 
intestine, two common sites of metastasis. After 2 weeks of VEGF-C 
induction, VEGF-C mRNA expression (1.19 ± 0.66 versus 1.00 ± 
0.27, P = 0.52, fig. S6A) and protein levels were comparable in the 
liver (3.31 ± 0.59 g/mg tissue versus 3.37 ± 0.84 g/mg tissue, P = 
0.89, fig. S6B) and intestine (mRNA: 1.04 ± 0.25 versus 1.00 ± 0.12, 
P = 0.75, fig. S6A; protein: 47.99 ± 17.94 pg/mg tissue versus 54.79 ± 
13.42 pg/mg tissue, P = 0.47, fig. S6B). VEGF-C protein levels 
were slightly higher in the serum (24.85 ± 12.69 pg/ml versus 13.52 ± 
6.00 pg/ml, P = 0.14, fig. S6B). The density and morphology of LVs 
in the intestine and liver were comparable in CCSP × VEGFC and 
control mice (fig. S6, C and E). The width of intestinal lacteals was 
similar in CCSP × VEGFC and control mice (fig. S6D).
As mechanisms of lung colonization after tail vein injection of 
B16F10 cells are likely to differ from spontaneously forming lung 
metastases, we next investigated the effects of increased lung lym-
phatic density in the 4T1 orthotopic breast cancer model. CCSP × 
VEGFC mice, bred into the BALB/c background, showed a similar 
extent of lung lymphangiogenesis as CCSP × VEGFC mice on the 
C57BL/6 background when a higher dose (2 mg/ml) of doxycycline 
was used (fig. S7). As before, 1 × 105 4T1-luc2 cells were orthotopi-
cally injected and primary tumors were removed after 21 days. Four 
days after the surgery, VEGF-C overexpression was induced in the 
lung. On days 7, 14, and 21, in vivo IVIS imaging was performed to 
detect the metastases, and 21 days after the surgery, lungs and other 
organs were resected after euthanization and were quantified ex vivo 
Fig. 3. Characterization of CCSP-rtTA × tet-O–VEGF-C mice after doxycycline treatment for 2 weeks. (A) VEGF-C mRNA expression in the lung (normalized to RPLP0). 
The average expression level in WT × tet-O–VEGF-C mice was set to 1 (n = 6). (B) VEGF-C protein levels in the lung detected by enzyme-linked immunosorbent assay 
(ELISA) (n = 6). (C) Quantification of the VEGFR3+ LV area (n = 4). (D) Representative images of VEGFR3 staining in the lung. Scale bars, 1 mm. (E) Representative high- 
magnification images of different regions in the lung stained for VEGFR3. Scale bars, 200 m. PA, pulmonary artery; PV, pulmonary vein. (F) Representative images of 
MECA-32 staining in the lung. Scale bars, 50 m. (G) Quantification of MECA-32+ blood vessel area in the lung (n = 5).
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Fig. 4. Increased metastasis in CCSP-rtTA × tet-O–VEGF-C mice after tail vein injection of B16F10 melanoma cells. (A) Schematic of the B16F10 tumor study. 
Dox, doxycycline; i.v., intravenous. (B) Representative images of lung sections with metastatic nodules 14 days after tumor cell injection (indicated by staining for 
RFP from B16F10-luc2-tdTomato cells). Scale bars, 1 mm. (C) Quantification of tdTomato+ area in the lung 14 days after tumor cell injection (n = 10). (D) Quantification 
of tdTomato+ cells per lung 24 hours after intravenous injection of 1 × 106 B16F10-luc2-tdTomato cells. (E) Representative images of lymphatic invasion (white arrows) 
with orthogonal projection. Scale bars, 100 m. Fisher’s exact test was performed. (F) Quantification of the lung-draining lymph node weight (n = 10). (G) Number of 
mice with different numbers of distant organs with metastasis (zero, one, two, or three organs affected) and example images of metastases (yellow arrows) in the liver 
and intestine. Data were pooled from two rounds of studies.
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(Fig. 5A). The primary tumor growth (fig. S8, A and B) and the in-
cidence of lung metastasis (fig. S8C) at the time of primary tumor 
removal were comparable. Twenty-one days after primary tumor 
removal (17 days after induction of VEGF-C), overt lung metasta-
sis was detectable in 8 of 16 mice in the control group. Of these, one 
mouse had to be euthanized before the predefined study end point. 
In mice with VEGF-C overexpression in the lung, 11 of 16 mice 
showed detectable lung metastases, of which 3 mice reached the eu-
thanization criteria before the end point. Because of the high vari-
ability of spontaneously formed metastasis, we did not observe a 
significant difference in nodule number and size (fig. S9). Strikingly, 
the metastatic load over the whole body, monitored by biolumi-
nescence imaging, was much greater in CCSP × VEGFC mice 
(Fig. 5, B and C). CCSP × VEGFC mice were 4.8 times more likely 
to have metastasis in other organs compared to the control group 
(7 of 11 mice in the CCSP × VEGFC group versus 2 of 8 mice in the 
control group; odds ratio, 4.8; P = 0.17, Fisher’s exact test). Quasi- 
Poisson regression analysis estimated that 2.9 times more organs were 
affected in CCSP × VEGFC mice than in control mice (1.45 organs 
per mouse in CCSP × VEGFC mice versus 0.5 in control mice; P = 
0.13; Fig. 5D and fig. S10). Together, these data further support the 
concept that metastasis-associated lymphatics might facilitate the 
spread of lung metastases to other organs.
DISCUSSION
In many cancer types, including melanoma and breast cancer, VEGF-C 
expression, tumor-associated lymphangiogenesis, and lymphatic in-
vasion within the primary tumor correlate with poor patient outcome 
and have been suggested as prognostic markers (1–3).  In this study, we 
demonstrate that lymphangiogenesis is also induced at sites of me-
tastasis. Lymphangiogenesis and the presence of lymphatic inva-
sion within and around metastases in the lung correlated with poor 
outcome in a cohort of melanoma patients. Lymphatic density and 
invasion in metastases could serve as prognostic factors for late- stage 
melanoma patients with visceral organ metastasis or for patients with 
melanoma metastases but without apparent primary tumor.
Increased LV density at metastatic sites, especially in combination 
with lymphatic invasion, could facilitate further lymphatic spread 
of metastatic cells from established metastases at the distant sites. In 
our cohort of melanoma patients, lymphangiogenesis and lymphatic 
invasion in and around metastases in the lungs correlated with the 
presence of metastases in hilar lymph nodes. Similarly, in experi-
mental tumor models, greater lymphatic area in metastasis-bearing 
lungs and greater weight of the tracheobronchial lymph node were 
associated with the presence of further distant metastasis. Using a 
transgenic mouse model with inducible VEGF-C expression and 
lymphangiogenesis in the lung, we found greater growth of experi-
mental melanoma metastases in the lungs and more metastases in 
other organs in both the melanoma and the breast cancer model. 
The further distant metastatic spread from lung metastases seems to 
be mediated by the increased access to LVs and not just by enhanced 
growth of lung metastases, because there was no major difference in 
the distant metastasis rate in CCSP × VEGFC mice with high versus 
low metastatic load in the lung. Accordingly, the incidence of lym-
phatic invasion and the weight of draining lymph nodes were both 
greater in lungs with expanded lymphatics after VEGF-C overex-
pression. These findings are in agreement with a previous study in 
nude mice, where VEGF-C overexpression in the tumor cells pro-
moted intralymphatic spread of lung metastases (24). It will be of 
great interest to investigate, in future studies, whether LVs might 
also promote the growth and/or further spread of metastases in other 
organs than the lungs.
The contribution of lymph node metastasis to metastases in other 
organs has remained unclear, although the detection of sentinel lymph 
node metastasis is associated with reduced survival in many tumor 
Fig. 5. Increased metastasis in CCSP-rtTA × tet-O–VEGF-C mice in the 4T1 spontaneous breast cancer metastasis model. (A) Schematic of the 4T1 tumor study. PR, 
postremoval; s.c., subcutaneous. (B) Representative in vivo bioluminescence images of metastases on day 21 after primary tumor removal. (C) Quantification of biolumi-
nescence signal over the whole body on days PR7, PR14, and PR21 by IVIS imaging. For data from days PR7 and PR14, WT × VEGFC, n = 8, and CCSP × VEGFC, n = 11. Four 
mice reached the euthanization criteria before the end time point; thus, for data from day PR 21, WT × VEGFC, n = 7, and CCSP × VEGFC, n = 8. ns, not significant. 
(D) Number of mice with different numbers of distant organs with metastasis (zero, one, two, or three organs affected). Data were pooled from three rounds of studies. 
Only mice with detectable metastases (by ex vivo IVIS imaging) in the lungs were quantified.
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types (1, 2). However, surgical resection of regional lymph nodes 
did not improve the overall survival rate compared to radiation and 
systemic therapy without surgical resection of regional lymph nodes 
in melanoma and breast cancer patients (12–14). Our results pro-
vide a possible explanation for this apparent discrepancy; the pres-
ence of sentinel lymph node metastasis might reflect the potential of 
disseminated tumor cells to induce lymphangiogenesis at distant sites, 
which might promote further metastatic progression to other dis-
tant organs. In line with this hypothesis, chemokines produced by 
LECs have been reported to attract CXCR4-expressing melanoma 
stem-like cells, resulting in a “lymphovascular niche,” whereas CCR7, 
the receptor for the lymphatic chemokine CCL21, promoted stem-
ness in breast cancer (7, 25).
Our finding that the density of blood vessels in the lung was un-
affected despite the large expansion of the lymphatic network by 
VEGF-C overexpression is in line with previous studies in which 
lymphangiogenesis, but not angiogenesis, was found in transgenic 
mice overexpressing VEGF-C (26, 27). Although the mature form of 
VEGF-C can bind to the major angiogenesis receptor VEGFR2 on 
blood vascular endothelium, its affinity for VEGFR3 is much higher 
(28). Together with our finding that extravasation of tail vein– injected 
tumor cells from the bloodstream to the lung parenchyma was not 
increased in VEGF-C–overexpressing lungs, an influence of blood 
vessel activation on metastatic growth and secondary organ-to-organ 
metastasis via blood vessels seems unlikely. A direct mitogenic ef-
fect of VEGF-C on metastatic tumor cells also seems unlikely, be-
cause we could not detect VEGFR3 expression on B16F10 and 4T1 
cells by quantitative polymerase chain reaction (qPCR) and immuno-
fluorescence staining, and because there was no increase in the pro-
liferation rate of B16F10 cells upon VEGF-C treatment in vitro.
In conclusion, our study shows that, besides promoting the spread 
of tumor cells from primary tumors to tumor-draining lymph nodes, 
lymphangiogenesis can also facilitate further metastasis by promoting 
the growth of metastases in distant organs and their further dissemi-
nation to other distant organs. Anti-lymphangiogenic agents could 
have beneficial effects in patients with metastatic cancers.
MATERIALS AND METHODS
Mice
C57BL/6J and BALB/c WT mice were obtained from Janvier. CCSP- 
rtTA × tet-O–VEGF-C mice (22, 23) were backcrossed into the 
C57BL/6 and BALB/c backgrounds. Prox1-GFP mice were provided 
by Y.-K. Hong, University of Southern California (29). All mice were 
housed under specific pathogen–free conditions. The overexpression 
of VEGF-C in CCSP-rtTA × tet-O–VEGF-C mice was induced by 
administration of doxycycline (1 mg/ml, C57BL/6 mice; 2 mg/ml, 
BALB/c mice) in drinking water (containing 5% sucrose) for 2 weeks, 
starting at 8 weeks of age.
Tumor studies
For the B16F10 metastasis model, 5 × 105 B16F10-luc2-tdTomato 
cells were suspended in 200 l of phosphate-buffered saline (PBS) 
and injected into the tail vein. The mice were monitored three times 
a week for up to 3 weeks. For the 4T1-luc2 spontaneous breast cancer 
metastasis model, 1 × 105 tumor cells were suspended in 50 l of 
PBS and injected into the fourth mammary fat pad of BALB/c mice. 
The primary tumor growth was monitored every 3 days for 3 weeks 
until the primary tumors were surgically removed. After the sur-
gery, mice were monitored three times a week for another 3 weeks. 
The mice were euthanized with an overdose of anesthesia [ketamine 
(1000 mg/kg), Ketasol, Graeub; medetomidine (3.5 mg/kg), Domitor, 
Provet], and tissues were collected for analysis. All tumor studies 
were performed in agreement with the regulations of the local ethical 
board of Kantonales Veterinäramt Zürich, under license ZH012/15.
Retrospective lung metastasis study
The information on melanoma patients and lung samples was col-
lected at the Department of Dermatology at the University Hospital 
Zurich. Resected lung samples of patients with melanoma metastasis 
(n = 26) were sectioned at a thickness of 4 m and stained for podo-
planin (clone D2-40, BioLegend). The LV hotspots around and within 
metastases were imaged on a Zeiss Axioskop 2 MOT Plus microscope 
with a 20× objective. The LV number and lymphatic area percentages 
were quantified in a blinded manner from patient information. Five 
hotspots per sample were analyzed, and the average value was calcu-
lated for each sample. The incidence of lymphatic invasion was deter-
mined on the basis of the entire sample. The local ethics committee 
approved the written informed consent for tissue storage including the 
retrospective analysis with collection of clinical/laboratory/ histological 
information before collection (Kantonale Ethikkommission Zürich, 
Biobank/Sammlung von Tumorgewebe, KEK-ZH-Nr. 647).
Tissue processing and immunofluorescence staining
For lung staining, the mouse lungs were filled with 2% low-melt agar-
ose (Bio-Rad) through the trachea before dissection, chilled down 
in ice-cold PBS, and fixed in 4% paraformaldehyde (PFA) for 2 hours. 
For sectioning, agarose-filled lungs were embedded in 2% low-melt 
agarose and sectioned by Vibratome (Leica VT1000 S) into 200-m-
thick slices before staining. In the studies to compare the pulmonary 
lymphatic density in CCSP × VEGFC with WT × VEGFC mice, trans-
verse sections from the part near the left bronchial branch of the left 
lobe were used for staining. In the study to compare the pulmonary 
lymphatic density in the lungs of control and 4T1-injected mice, trans-
verse sections were made at the position of the detected nodules and 
corresponding positions in the control lungs. For the lungs without 
visible nodules on the surface, sections from the part near the left 
bronchus of the left lobe were used. For lacteal staining, approxi-
mately 1 cm of small intestine after the pancreatic curve was dissected, 
and the tube was cut longitudinally and pinned down (inside up) in 
silicone gel–coated six-well plates and fixed in 4% PFA for 2 hours 
at 4°C before staining. For liver staining, the right lobe of the mouse 
liver was dissected and fixed in 4% PFA for 2 hours at 4°C. Longitudinal 
sections (200 m) were cut by Vibratome (Leica VT1000 S) before 
staining. Lymph nodes and other organs were dissected, embedded 
in OCT (optimal cutting temperature) compound, snap-frozen, and 
stored at −80°C until preparation of cryosections (7 m).
For immunofluorescence stainings, sections were fixed with 
4% PFA for 20 min, rinsed with PBS, and blocked in PBS with 
0.2% bovine serum albumin, 5% donkey serum, and 0.3% Triton 
X-100 (blocking solution). Primary antibodies suspended in the 
blocking solution were incubated at room temperature for 2 hours 
or at 4°C overnight, followed by extensive washing and incubation 
with secondary antibodies. The antibodies used were Thy1.2 (rat, 
eBioscience), cytokeratin (wide spectrum, rabbit, Dako), LYVE-1 
(rabbit, AngioBio), SMA-Cy3 (mouse, Sigma-Aldrich), VEGFR3 
(goat, R&D Systems), MECA-32 (rat, BD), RFP (rabbit, Rockland), 
podoplanin (goat, R&D Systems), and CD31 (rat, BD Pharmingen).
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Image analysis
Images were taken on a Zeiss Axioskop 2 MOT Plus microscope 
with 10× or 20× objective, or a Zeiss LSM 880 upright confocal micro-
scope with 20× objective. Image analysis was performed using ImageJ 
(National Institutes of Health). For the quantification of the Thy1+ 
lymphatic area, structures smaller than 150 m2 were excluded.
Bioluminescence and stereomicroscope imaging
Bioluminescence imaging was performed with an IVIS Spectrum 
system (PerkinElmer). Fifteen minutes after intraperitoneal injection 
of d-luciferin (10 µl/g; 15 mg/ml in PBS; PerkinElmer), mice were 
anesthetized by inhalation of 2% isoflurane in O2, placed on the 
temperature control platform of the IVIS machine, and imaged in 
vivo. After euthanization, mice were dissected and organs were 
imaged ex vivo. The intensity of luminescence signals was quan-
tified by Living Image Software (PerkinElmer). This luminescence 
imaging method can detect as few as 50 tumor cells in the lymph 
node. Stereomicroscope imaging was performed with a Zeiss Axio 
Zoom.V16 microscope and a QImaging optiMOS sCMOS camera 
(QImaging), combined with a light-emitting diode illumination 
system (pE-4000, CoolLED Ltd.).
Cell lines
B16F10 cells expressing luciferase (luc2) and tdTomato were 
generated and described previously (30). Cells were cultured in 
Dulbecco’s modified Eagle medium (DMEM) containing GlutaMAX, 
pyruvate, 10% fetal bovine serum (FBS), and penicillin/streptomycin 
(Gibco/Thermo Fisher). G418 (1.5 mg/ml; Roche) was added to 
the culture medium to ensure stable expression of the tdTomato 
transgene. 4T1 mammary carcinoma cells expressing luciferase 
(luc2) (PerkinElmer) were maintained in DMEM supplemented with 
l-glutamine, 10% FBS, and penicillin/streptomycin under standard 
culture conditions (37°C, 5% CO2).
RNA extraction and qPCR
RNA from snap-frozen tissues was extracted using the NucleoSpin 
RNA Kit (Macherey-Nagel) according to the manufacturer’s instruc-
tions. The intestinal tissue was snap-frozen after removal of the fat 
tissue, and RNA was extracted using the RNeasy Lipid Tissue Mini Kit 
(Qiagen). RNA was reverse-transcribed using the High-Capacity cDNA 
Kit (Applied Biosystems/Thermo Fisher). qPCR analyses were per-
formed on a 7900HT FAST instrument (Applied Biosystems/Thermo 
Fisher) in triplicate using SYBR Green (Roche). RPLP0 was used as 
an internal reference gene. Relative expression (RE) was calculated 
according to the formula REgeneX = 2−(CtgeneX − CtRPLP0) and was 
expressed as fold change normalized to the control condition. 
The primer sequences used for qPCR were as follows: RPLP0, 
5′-AGATTCGGGATATGCTGTTGG-3′ (forward) and 5′-TCGG-
GTCCTAGACCAGTGTTC-3′ (reverse); VEGFC, 5′-GGGGGCGA-
GGTCAAGGCTTTT-3′ (forward) and 5′-CCTGGTATTGAGGGT-
G GGCTGC-3′ (reverse).
Enzyme-linked immunosorbent assay
Tissue samples were resected, snap-frozen, and kept at −80°C. Blood 
(500 l) was collected in Capiject tubes (Terumo), left at room tem-
perature for 20 min, and centrifuged at 1200g for 10 min. The serum 
was collected, snap-frozen, and kept at −80°C. For each tissue sam-
ple, 100 mg of tissue was homogenized in 1 ml of PBS and diluted by 
1:250 (lung and intestine) or 1:5000 (liver) with PBS before measure-
ments. Mouse VEGF-C levels were measured using a mouse VEGF-C 
ELISA kit (Cusabio), following the manufacturer’s instructions.
Lung homing assay
B16F10-luc2-tdTomato cells (1 × 106) were injected into the tail vein. 
After 24 hours, the lung was perfused, resected, minced, and digested 
in a collagenase solution (Collagenase II, 2 mg/ml, Sigma-Aldrich; 
deoxyribonuclease I, 40 g/ml, Roche) for 45 min at 37°C. The digested 
tissue was passed through a 40-m cell strainer before erythrocyte 
lysis with Pharm Lyse (BD). After washing and a second filtration 
step, the cell suspension was labeled with CD45-APC/Cy7 (103116, 
BioLegend). 7-AAD (7-aminoactinomycin D; 420404, BioLegend) was 
used for life/dead discrimination. CD45-negative, tdTomato-positive 
cells were counted as tumor cells homed into the lungs.
Statistical analyses
Statistical analyses were performed with GraphPad Prism 5 (GraphPad 
Software Inc.). Graphs represent means ± SD. Student’s t test was 
used to compare two groups. One-way ANOVA was used to compare 
three groups. Other types of tests are indicated in the text or the 
figure legends. A P value of <0.05 was considered statistically signifi-
cant (indicated by asterisks).
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